Hercules Capital Appoints Two Senior Investment Professionals in New Leadership Roles
Both will continue to report to Scott Bluestein, interim chief executive officer and chief investment officer of Hercules.
Hercules
Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the
largest specialty financing provider to innovative venture growth stage
companies backed by leading venture capital and private equity firms,
today announced the promotions of R. Bryan Jadot to Head of Life
Sciences Venture Lending and Steve Kuo to Head of Technology Venture
Lending. Jadot and Kuo each served long-term tenures of more than 13
years at Hercules, respectively, and have made significant contributions
to the growth of the Company’s debt and equity investment portfolio
which stands at more than $2.1 billion today. Both will continue to
report to Scott Bluestein, interim chief executive officer and chief
investment officer of Hercules.
“Both Bryan and Steve have made significant contributions to the firm,
each demonstrating their industry insights and value to the expansion
and success of our industry-leading venture lending platform,” stated
Scott Bluestein. “Based on their proven track record and experience
growing our two largest investment groups, we are proud to recognize
them for their accomplishments and we look forward to their continued
leadership of our venture life sciences and venture technology groups. I
have worked closely with Bryan and Steve since 2010 and I am confident
that these promotions will position us best for continued success and
platform expansion. Moving forward, we will continue to
opportunistically and strategically make investments in our organization
that helps achieve our growth objectives for the year and supports our
vision of becoming a broader provider of specialty debt financing
solutions.”
R. Bryan Jadot is the Head of Venture Lending for the Life
Sciences Group and brings nearly 20 years of financial and credit
structuring experience to Hercules. Prior to joining Hercules in 2005,
Mr. Jadot served as vice president of the Life Sciences Group at Silicon
Valley Bank in Newton, MA where he co-managed a banking group dedicated
to New England-based life science clients including biotechnology,
medical device, and healthcare IT clients. He also worked as the vice
president of the Software Group at Silicon Valley Bank in Palo Alto, CA.
Prior to Silicon Valley Bank, Mr. Jadot worked with the Corporate
Banking arm of the Banque Nationale de Paris in San Francisco, CA and
was an assistant economist with the Department of Treasury’s Office of
Eastern Europe and former Soviet Union in Washington DC.
Steve Kuo is the Head of Venture Lending for the Technology Group
at Hercules and brings more than 16 years of operational and structured
finance experience. Since joining Hercules in 2006, he has led over $1.2
billion in capital investments. Mr. Kuo was appointed a co-head of
Hercules Capital SaaS Finance division in 2018 and has been involved
with early stage startups with passionate founders and great concepts as
well as billion-dollar revenue businesses looking to finance their next
big market. Prior to Hercules, he was a strategic member of Lightcross,
a silicon photonics startup, where he led the product management team.
Before joining Lightcross, he was a principal at Comdisco Ventures.
About Hercules Capital, Inc.
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) is the leading and
largest specialty finance company focused on providing senior secured
venture growth loans to high-growth, innovative venture capital-backed
companies in a broad variety of technology, life sciences and
sustainable and renewable technology industries. Since inception
(December 2003), Hercules has committed more than $8.9 billion to over
460 companies and is the lender of choice for entrepreneurs and venture
capital firms seeking growth capital financing. Companies interested in
learning more about financing opportunities should contact [email protected],
or call 650.289.3060.
Hercules’ common stock trades on the New York Stock Exchange (NYSE)
under the ticker symbol “HTGC.” In addition, Hercules has six
outstanding bond issuances of:
Institutional Notes PAR $1000.00
- 4.625% Notes due 2022
Retail Notes (“Baby Bonds”) PAR $25.00
- 5.25% Notes due 2025 (NYSE: HCXZ)
- 6.25% Notes due 2033 (NYSE: HCXY)
Convertible Notes
- 4.375% Convertible Notes due 2022
Securitization Notes
- 4.605% Asset-backed Notes due 2027
- 4.703% Asset-backed Notes due 2028
Forward-Looking Statements
This press release may contain “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. You
should understand that under Section 27A(b)(2)(B) of the Securities Act
of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995 do
not apply to forward-looking statements made in periodic reports we file
under the Exchange Act.
The information disclosed in this press release is made as of the date
hereof and reflects Hercules’ most current assessment of its historical
financial performance. Actual financial results filed with the SEC may
differ from those contained herein due to timing delays between the date
of this release and confirmation of final audit results. These
forward-looking statements are not guarantees of future performance and
are subject to uncertainties and other factors that could cause actual
results to differ materially from those expressed in the forward-looking
statements including, without limitation, the risks, uncertainties,
including the uncertainties surrounding the current market volatility,
and other factors the Company identifies from time to time in its
filings with the SEC. Although Hercules believes that the assumptions on
which these forward-looking statements are based are reasonable, any of
those assumptions could prove to be inaccurate and, as a result, the
forward-looking statements based on those assumptions also could be
incorrect. You should not place undue reliance on these forward-looking
statements. The forward-looking statements contained in this release are
made as of the date hereof, and Hercules assumes no obligation to update
the forward-looking statements for subsequent events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005165/en/